TheraRadar
Clinical-Stage Companies / Zai Lab (Shanghai)

Zai Lab (Shanghai)

Pre-Approval PRO BETA
18
Total Trials
3
Phase 3
6
Phase 2
6
Recruiting
151
Score

Pipeline by Phase

Phase 3
3
Phase 2
6
Phase 1
11

Therapeutic Focus

Solid Tumors Ovarian Cancer Gastrointestinal Stromal Tumor(GIST) SCLC Small-cell Lung Cancer

Clinical Trials (18)

NCT07218146 Phase 3 RECRUITING

A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)

Started: 11/30/2025

NCT07211776 Phase 3 RECRUITING

A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease

Started: 12/5/2025

NCT03516084 Phase 3 TERMINATED

A Study of Niraparib as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer

Started: 8/20/2018

NCT04633122 Phase 2 COMPLETED

A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib

Started: 11/25/2020

NCT04282980 Phase 2 COMPLETED

A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST)

Started: 4/23/2020

NCT04392102 Phase 2 COMPLETED

A Study of Niraparib in Patients With Relapsed Ovarian Cancer

Started: 8/4/2020

NCT03516071 Phase 2 COMPLETED

A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC

Started: 5/17/2017

NCT06885281 Phase 1 RECRUITING

A Study of ZL-1310 in Participants With Selected Solid Tumors

Started: 5/12/2025

NCT06179069 Phase 1 RECRUITING

A Study of ZL-1310 in Subjects With Small Cell Lung Cancer

Started: 1/23/2024

NCT07374848 Phase 1 RECRUITING

Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors

Started: 3/1/2026

NCT07235384 Phase 1 RECRUITING

A Phase 1/1b Study to Evaluate Safety, Tolerability and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic Dermatitis

Started: 12/1/2025

NCT04212221 Phase 1 TERMINATED

MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in Advanced Liver Cancer Patients

Started: 4/20/2020

NCT04653038 Phase 1 TERMINATED

A Study to Evaluate the Safety and Efficacy of MGD013 in Patients With Melanoma

Started: 10/29/2020

NCT05866354 Phase 1 COMPLETED

To Evaluate Pharmacokinetics of Tisotumab Vedotin in Chinese Subjects With Metastatic or Recurrent Solid Malignancies

Started: 6/16/2023

NCT04257617 Phase 1 COMPLETED

A Trial of ZL-1201 in Subjects With Advanced Cancer

Started: 5/11/2020

NCT04178460 Phase 1 TERMINATED

A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment

Started: 2/3/2020

NCT04398108 Phase 1 COMPLETED

A Study to Evaluate the Pharmacokinetics of Margetuximab in Chinese Patients With HER2+ MBC

Started: 8/25/2020

NCT03551171 Phase 1 COMPLETED

The Clinical Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of ZL-2306 (Niraparib) in Patients With Ovarian Cancer

Started: 12/19/2017

Drug Candidates

ZL-1310 Ripretinib Sunitinib Atezolizumab Carboplatin Investigator's Choice of Therapy ZL-6201 ZL-1109 (VRDN-003) Placebo ZL-1503
Activity Status: Active
Last Trial Started: 3/1/2026
Last Trial Ended: 11/2/2023
Trials (12 months): 5
Completed Trials: 8
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.